Anlotinib Hydrochloride in Intra-Abdominal Desmoplastic Small Round Cell Tumors: Technical Insights from First Clinical Evidence

Study Background and Research Question

Intra-abdominal desmoplastic small round cell tumor (IADSRCT) represents a rare and highly aggressive sarcoma, most commonly affecting young males. Characterized by the EWS-WT1 fusion protein, IADSRCT exhibits poor prognosis, with five-year survival rates rarely exceeding 30%. Due to its rarity and histopathological complexity, no standardized treatment guidelines exist, and current approaches typically combine surgical resection, intensive chemotherapy, and occasionally radiotherapy. However, metastatic recurrences are common, and treatment options after first-line therapy failure remain extremely limited. The reference study (Chen & Feng, 2019) addresses whether anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor (TKI), can provide therapeutic benefit in metastatic IADSRCT where conventional protocols have been exhausted.

Key Innovation from the Reference Study

This report by Chen and Feng is the first documented clinical use of anlotinib hydrochloride in IADSRCT. Anlotinib is an orally available multi-target receptor TKI with potent inhibitory activity against VEGFR1-3, FGFR1-4, PDGFRα/β, c-Kit, and Met. While prior work has validated its efficacy in other solid tumors, including non-small cell lung cancer and renal cell carcinoma, its application in sarcomas—particularly IADSRCT—had not previously been described. The key innovation lies in demonstrating that anlotinib can induce rapid and marked regression of metastatic lymph nodes in a patient with chemo-refractory IADSRCT, with tolerable toxicity, thus opening a novel avenue for anti-angiogenic therapy in this otherwise treatment-refractory context (reference).

Methods and Experimental Design Insights

The study reports a detailed clinical case of a 38-year-old male presenting with an anterior abdominal wall nodule and a large intraperitoneal mass. After initial surgical debulking and pathological confirmation of IADSRCT (including immunohistochemistry for AE1/AE3, desmin, NSE, CD99, and others), the patient received six cycles of adjuvant chemotherapy. Disease progression was detected by CT, revealing new right inguinal and omental lymph node metastases. At this point, anlotinib was initiated as salvage therapy. The clinical protocol involved the oral administration of anlotinib; although the precise dosing regimen is not detailed in the case report, phase I and II trials in other indications have typically used a 12 mg once-daily regimen in 2-weeks-on, 1-week-off cycles.

• Tumor assessment: Serial CT imaging to monitor nodal size and response.
• Toxicity monitoring: Routine laboratory and clinical screening for adverse effects (notably hypertriglyceridemia and fatigue).

Protocol Parameters

• Anlotinib administration: Although this report does not specify dose, established research protocols often use 12 mg orally, once daily, for 14 days followed by a 7-day rest, per 21-day cycle, in adult solid tumor patients.
• Imaging schedule: Baseline and every 2 cycles (6 weeks) using contrast-enhanced CT to assess tumor and nodal response.
• Safety and laboratory monitoring: Lipid profile, liver and renal function every cycle; adverse event reporting per CTCAE v4.0 or later.

Core Findings and Why They Matter

After four cycles of anlotinib, the patient experienced significant regression of both right inguinal and omental lymph node metastases, as evidenced by CT imaging. Anlotinib was subsequently continued as maintenance, with the patient remaining in good clinical condition at follow-up. The only notable side effects were elevated triglycerides and fatigue, both manageable and not dose-limiting. These findings underscore several technical and translational insights:

• Multi-pathway angiogenesis inhibition: Anlotinib's blockade of VEGFR, PDGFR, and FGFR axes likely contributed to rapid reduction in nodal tumor burden, consistent with its mechanism as a broad-spectrum anti-angiogenic small molecule (product information).
• Clinical tolerability: The manageable toxicity profile aligns with preclinical and early phase trial data reporting low off-target cytotoxicity at pharmacologically active doses.
• Translational potential: This case supports the hypothesis that targeting tumor angiogenesis, via ERK signaling pathway inhibition downstream of VEGFR/PDGFR/FGFR, can yield tangible benefit even in aggressive, poorly differentiated sarcomas where standard chemotherapy has failed.

Importantly, this report provides the first clinical rationale for integrating multi-target tyrosine kinase inhibition in the treatment algorithm for IADSRCT, a domain previously devoid of targeted options (reference).

Comparison with Internal Literature and Broader Research Context

Several recent internal reviews contextualize the pharmacological sophistication of anlotinib hydrochloride. For example, in a mechanistic overview (MAP Kinase Fragment), anlotinib is benchmarked for its nanomolar potency against VEGFR2, PDGFRβ, and FGFR1, and its superiority over legacy TKIs such as sunitinib and sorafenib in both endothelial cell migration inhibition and capillary tube formation assays. This aligns mechanistically with the clinical response observed in the IADSRCT case, where rapid nodal regression is likely attributable to the compound's broad anti-angiogenic and anti-proliferative actions.

Further, internal articles (ERK12; Z-VAD-FMK) highlight the utility of anlotinib in advanced cancer research, emphasizing its predictable pharmacokinetics, high oral bioavailability, and low cytotoxicity in functional assays. The translational bridge from in vitro endothelial cell migration and ERK signaling pathway inhibition to clinical anti-tumor activity, as documented in the reference case report, underscores the value of integrating these preclinical workflow insights with real-world patient outcomes.

Limitations and Transferability

As a single case report, the evidence is inherently limited by lack of a control group, short follow-up, and potential for idiosyncratic response. The optimal dosing schedule, duration of therapy, and selection of patients most likely to benefit remain undefined for IADSRCT. Furthermore, the generalizability of these findings to other sarcoma subtypes or to patients with differing genetic backgrounds is unknown. Additional clinical studies—ideally multi-institutional case series or basket trials—are required to establish efficacy, safety, and biomarker-driven selection criteria for anlotinib in this rare tumor type.

Research Support Resources

Researchers seeking to model or extend these findings in preclinical or translational studies may consider using Anlotinib hydrochloride (SKU C8688) as a reference-grade research tool. This compound offers well-characterized selectivity for VEGFR2, PDGFRβ, and FGFR1 with minimal cytotoxicity at functional concentrations, making it suitable for endothelial cell migration inhibition, capillary tube formation assays, and related ERK pathway studies. Detailed workflow and benchmarking resources are available through APExBIO and cited internal technical articles, supporting rigorous cancer research and angiogenesis inhibition protocols.